108 related articles for article (PubMed ID: 8251883)
1. Cytokinetic considerations relevant to development of a successful therapeutic strategy in chronic myelogenous leukemia (CML).
Clarkson B; Strife A
Leuk Lymphoma; 1993; 11 Suppl 1():101-7. PubMed ID: 8251883
[TBL] [Abstract][Full Text] [Related]
2. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
Clarkson B; Strife A
Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
4. The biology of normal and neoplastic stem cells in CML.
Eaves C; Udomsakdi C; Cashman J; Barnett M; Eaves A
Leuk Lymphoma; 1993; 11 Suppl 1():245-53. PubMed ID: 8251904
[TBL] [Abstract][Full Text] [Related]
5. Integration of molecular and biological abnormalities in quest for selective treatment of chronic myelogenous leukemia (CML).
Clarkson B; Strife A; Perez A; Lambek C; Wisniewski D
Leuk Lymphoma; 1993; 11 Suppl 2():81-100. PubMed ID: 8124237
[TBL] [Abstract][Full Text] [Related]
6. Clonal expansion after bone marrow transplantation in a patient with chronic myelogenous leukemia.
Macera MJ; Botti AC; Verma RS; Coleman M; Thomas ED
Blut; 1988 Nov; 57(5):303-6. PubMed ID: 3058235
[TBL] [Abstract][Full Text] [Related]
7. [Chronic myeloid leukemia. New prospects for marrow autotransplantation].
Carella AM; Carlier P; Nati S; Congiu A; Pierluigi D; Raffo MR
Haematologica; 1991 Jun; 76 Suppl 3():337-51. PubMed ID: 1684348
[No Abstract] [Full Text] [Related]
8. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
Verfaillie CM; Hurley R; Lundell BI; Zhao C; Bhatia R
Acta Haematol; 1997; 97(1-2):40-52. PubMed ID: 8980609
[TBL] [Abstract][Full Text] [Related]
9. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
10. Cell biology of CML--a model linking the chronic and terminal phases.
Gordon MY
Leuk Lymphoma; 1993; 11 Suppl 1():93-100. PubMed ID: 8251924
[TBL] [Abstract][Full Text] [Related]
11. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
12. Stem cell factor and chronic myeloid leukemia CD34+ cells.
Moore S; McDiarmid LA; Hughes TP
Leuk Lymphoma; 2000 Jul; 38(3-4):211-20. PubMed ID: 10830729
[TBL] [Abstract][Full Text] [Related]
13. Potential mechanisms of action of interferon-alpha in CML.
Dowding C; Gordon M; Guo AP; Maison D; Osterholz J; Siczkowski M; Goldman J
Leuk Lymphoma; 1993; 11 Suppl 1():185-91. PubMed ID: 7504544
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
15. Characterization and selection of benign stem cells in chronic myeloid leukemia.
Lemoli RM
Haematologica; 1993; 78(6):393-400. PubMed ID: 8175034
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-beta on normal and leukemic human hematopoietic progenitor cells.
Cashman JD; Eaves AC; Eaves CJ
Leukemia; 1992 Sep; 6(9):886-92. PubMed ID: 1518302
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
19. Biology and treatment of chronic myelogenous leukemia.
Giles FJ; Kantarjian HM
Oncology (Williston Park); 1997 Sep; 11(9):1295-300; discussion 1302-10. PubMed ID: 9306419
[TBL] [Abstract][Full Text] [Related]
20. Differences between normal and CML stem cells: potential targets for clinical exploitation.
Eaves AC; Barnett MJ; Ponchio L; Cashman JD; Petzer AL; Eaves CJ
Stem Cells; 1998; 16 Suppl 1():77-83; discussion 89. PubMed ID: 11012149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
